The U.S. Food and Drug Administration has announced a voluntary recall of Vitruvias Therapeutics Inc. thyroid tablets due to potential superpotency [1].
This recall is critical because thyroid medication requires precise dosing. Tablets with excessive potency can disrupt hormonal balance, potentially leading to serious health complications for patients relying on the drug for endocrine stability.
The recall affects one lot [4] of the 30 mg [3] thyroid tablets, specifically Lot No. 504950 [3]. The medication was distributed nationwide [1].
The FDA said testing indicated that the tablets in this specific lot may be superpotent [1]. This increased strength poses a risk of causing hyperthyroidism, which occurs when the thyroid gland is overactive [1].
Patients experiencing hyperthyroidism may face various side effects. While some reports focus on the risk of an overactive thyroid [1], other reports indicate the superpotent medication may trigger other side effects [2].
Vitruvias Therapeutics initiated the voluntary recall to mitigate these risks. The company and the FDA said they are working to ensure the affected lot is removed from the supply chain to protect patient safety [4].
Healthcare providers and patients are encouraged to check their medication packaging for the specific lot number. Those using the recalled tablets should contact their physician to discuss alternative treatments, and manage any potential symptoms of thyroid overactivity.
“Testing indicated that the tablets in this specific lot may be superpotent.”
The recall highlights the volatility of thyroid hormone manufacturing, where small deviations in potency can shift a patient from a treated state of hypothyroidism into a dangerous state of hyperthyroidism. Because these medications are often taken daily for long periods, a superpotent batch can lead to systemic cardiovascular and metabolic stress before a patient realizes the dosage is incorrect.
